# US 2010/0144025 A1 · Hla-binding peptide, precursor thereof, dna fragment and recombinant vector encoding the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0144025 A1
- Document ID: US20100144025A1
- Status: Published application
- Kind: A1
- Application number: 12/444,988
- Filed: 2007-10-03
- Published: 2010-06-10
- Earliest claimed: 2006-10-12
- Assignees: NEC Corporation; Kochi University
- Inventors: Tomoya Miyakawa; Keiko Udaka
- Web page: https://patentgrep.com/patent/US20100144025A1

## CPC

- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

There is provided an HLA-binding peptide being excellent in binding affinity to an HLA-A type molecule. An HLA-binding peptide capable of binding to an HLA-A type molecule, including one or more amino acid sequences selected from the group consisting of SEQ ID NOs: 1 to 50, and being composed of 8 or more and 11 or less amino acid residues, is provided. All of the amino acid sequences are the amino acid sequences that are predicted to be capable of binding to an HLA-A molecule by using a prediction program utilizing an active learning method shown in FIG. 1.

## Claims

### Claim at position 1

1-11. (canceled)

### Claim 12

An HLA-binding peptide capable of binding to an HLA-A type molecule, characterized in that the peptide comprises one or more amino acid sequences selected from the group consisting of SEQ ID NOs: 1 to 50, and is composed of 8 or more and 11 or less amino acid residues.

### Claim 13 (depends on 12)

The HLA-binding peptide according to claim 12, characterized in that the peptide comprises one or more amino acid sequences selected from the group consisting of SEQ ID NOs: 1, 2, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 and 50.

### Claim 14 (depends on 12)

An HLA-binding peptide capable of binding to an HLA-A type molecule, characterized in that the peptide comprises an amino acid sequence in which one or two amino acid residues have been deleted, substituted or added in the amino acid sequence contained in the HLA-binding peptide according to claim 12, and that the peptide is composed of 8 or more and 11 or less amino acid residues.

### Claim 15 (depends on 12)

The HLA-binding peptide according to claim 12, characterized in that the HLA-binding peptide binds to an HLA-A24 molecule.

### Claim 16 (depends on 15)

The HLA-binding peptide according to claim 15, wherein the HLA-A24 molecule is an HLA-A2402 molecule.

### Claim 17 (depends on 12)

The HLA-binding peptide according to claim 12, characterized in that the HLA-binding peptide binds to an HLA-A2 molecule.

### Claim 18 (depends on 17)

The HLA-binding peptide according to claim 17, wherein the HLA-A2 molecule is an HLA-A0201 molecule.

### Claim 19 (depends on 17)

The HLA-binding peptide according to claim 17, wherein the HLA-A2 molecule is an HLA-A0206 molecule.

### Claim 20 (depends on 12)

A DNA fragment, characterized in that the DNA fragment comprises a DNA sequence encoding the HLA-binding peptide according to claim 12.

### Claim 21 (depends on 12)

A recombinant vector, characterized in that the recombinant vector comprises a DNA sequence encoding the HLA-binding peptide according to claim 12.

### Claim 22 (depends on 12)

An HLA-binding peptide precursor, in which the HLA-binding peptide precursor is converted into the HLA-binding peptide according to claim 12 in vivo in mammals.
